Bayer aims to sustainably improve performance with new organization
- Details
- Category: Bayer

Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
- Details
- Category: Pfizer

European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
- Details
- Category: Roche

Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
- Details
- Category: Bayer

TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer
- Details
- Category: Pfizer

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson's disease meets primary endpoint
- Details
- Category: Bayer

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies
- Details
- Category: Roche

More Pharma News ...
- Pfizer declares first-quarter 2024 dividend
- FDA grants Priority Review to Amgen's tarlatamab application for advanced small cell lung cancer
- AstraZeneca to acquire Icosavax
- Bayer and Salus Optima partner on AI-enabled healthy aging journey
- Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
- Bayer and Hurdle launch precision health strategic partnership
- Bayer invests 130 million EUR in new production facility for innovative parenteral products